Catabasis Pharmaceuticls Inc. (NASDAQ:CATB)‘s stock had its “outperform” rating reissued by equities researchers at Wedbush in a research note issued to investors on Thursday. They currently have a $17.00 price objective on the stock. Wedbush’s target price would suggest a potential upside of 249.79% from the company’s previous close.

Separately, Zacks Investment Research raised Catabasis Pharmaceuticls from a “hold” rating to a “buy” rating and set a $4.25 target price for the company in a research note on Tuesday, July 5th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average price target of $19.05.

Catabasis Pharmaceuticls (NASDAQ:CATB) traded up 3.18% during mid-day trading on Thursday, reaching $4.86. The company’s stock had a trading volume of 152,966 shares. The company has a 50 day moving average of $4.77 and a 200-day moving average of $4.74. Catabasis Pharmaceuticls has a 52-week low of $3.31 and a 52-week high of $10.83. The stock’s market cap is $74.75 million.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at

Catabasis Pharmaceuticls (NASDAQ:CATB) last posted its earnings results on Thursday, August 11th. The company reported ($0.61) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.65) by $0.04. Equities analysts forecast that Catabasis Pharmaceuticls will post ($2.47) earnings per share for the current year.

An institutional investor recently bought a new position in Catabasis Pharmaceuticls stock. Bridgeway Capital Management Inc. acquired a new stake in shares of Catabasis Pharmaceuticls Inc. (NASDAQ:CATB) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 27,700 shares of the company’s stock, valued at approximately $102,000. Bridgeway Capital Management Inc. owned 0.18% of Catabasis Pharmaceuticls at the end of the most recent reporting period. Institutional investors and hedge funds own 57.27% of the company’s stock.

Catabasis Pharmaceuticls Company Profile

Catabasis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics based on its Safely Metabolized And Rationally Targeted (SMART), a linker drug discovery platform. The SMART linker drug discovery platform enables to engineer product candidates that can modulate multiple targets in a disease.

5 Day Chart for NASDAQ:CATB

Receive News & Ratings for Catabasis Pharmaceuticls Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catabasis Pharmaceuticls Inc. and related companies with's FREE daily email newsletter.